Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Short Interest Update

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) saw a significant growth in short interest in October. As of October 31st, there was short interest totalling 5,100,000 shares, a growth of 7.8% from the October 15th total of 4,730,000 shares. Based on an average trading volume of 191,600 shares, the days-to-cover ratio is presently 26.6 days. Approximately 25.2% of the company’s shares are short sold.

Institutional Trading of Dianthus Therapeutics

A number of hedge funds have recently modified their holdings of DNTH. Quest Partners LLC grew its stake in Dianthus Therapeutics by 112,400.0% in the 3rd quarter. Quest Partners LLC now owns 1,125 shares of the company’s stock valued at $31,000 after buying an additional 1,124 shares during the last quarter. Fred Alger Management LLC boosted its holdings in shares of Dianthus Therapeutics by 52.5% during the third quarter. Fred Alger Management LLC now owns 9,633 shares of the company’s stock worth $264,000 after acquiring an additional 3,316 shares during the period. SG Americas Securities LLC acquired a new position in shares of Dianthus Therapeutics in the second quarter valued at approximately $112,000. MetLife Investment Management LLC increased its stake in shares of Dianthus Therapeutics by 129.1% during the third quarter. MetLife Investment Management LLC now owns 13,939 shares of the company’s stock worth $382,000 after purchasing an additional 7,854 shares during the period. Finally, American Century Companies Inc. lifted its holdings in Dianthus Therapeutics by 38.6% during the 2nd quarter. American Century Companies Inc. now owns 30,432 shares of the company’s stock worth $788,000 after purchasing an additional 8,473 shares during the last quarter. Institutional investors and hedge funds own 47.53% of the company’s stock.

Analysts Set New Price Targets

Several research firms have recently weighed in on DNTH. Raymond James lifted their price objective on Dianthus Therapeutics from $51.00 to $56.00 and gave the company an “outperform” rating in a report on Friday, November 8th. Robert W. Baird assumed coverage on shares of Dianthus Therapeutics in a research note on Friday, July 26th. They issued an “outperform” rating and a $58.00 target price for the company. Baird R W raised shares of Dianthus Therapeutics to a “strong-buy” rating in a research note on Friday, July 26th. HC Wainwright reaffirmed a “buy” rating and issued a $40.00 target price on shares of Dianthus Therapeutics in a research report on Monday, November 11th. Finally, Oppenheimer boosted their price target on Dianthus Therapeutics from $48.00 to $52.00 and gave the stock an “outperform” rating in a research report on Monday, November 11th. Eight investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus target price of $46.43.

Dianthus Therapeutics Stock Up 1.0 %

Shares of NASDAQ DNTH opened at $23.60 on Tuesday. Dianthus Therapeutics has a twelve month low of $6.58 and a twelve month high of $33.77. The company has a market cap of $698.56 million, a PE ratio of -9.44 and a beta of 1.84. The business’s 50 day moving average price is $27.50 and its two-hundred day moving average price is $26.70.

Dianthus Therapeutics (NASDAQ:DNTH) last posted its quarterly earnings results on Thursday, November 7th. The company reported ($0.74) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.15). Dianthus Therapeutics had a negative net margin of 1,250.32% and a negative return on equity of 21.68%. The business had revenue of $2.17 million during the quarter, compared to the consensus estimate of $1.07 million. As a group, research analysts anticipate that Dianthus Therapeutics will post -2.61 EPS for the current fiscal year.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.